A Phase 2 interventional study of psilocybin in Veterans with treatment-resistant depression

Study Description

A research study testing psilocybin (a psychedelic medicine) to help Veterans with depression that hasn't improved with other treatments, including those who also have PTSD

Study Details

Registry ID:

NCT07226232

Conditions:

Major Depression

Phase:

Phase 3

Target Enrollment:

240 participants

Start Date:

August 3, 2026

Age Range:

18–75 years

Healthy Volunteers:

No

Study Locations (5 sites)

• Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
  Philadelphia, PennsylvaniaUnited States, United States
• Birmingham VA Medical Center, Birmingham, AL
  Birmingham, AlabamaUnited States, United States
• Tuscaloosa VA Medical Center, Tuscaloosa, AL
  Tuscaloosa, AlabamaUnited States, United States
• VA Portland Health Care System, Portland, OR
  Portland, OregonUnited States, United States
• VA Puget Sound Health Care System Seattle Division, Seattle, WA
  Seattle, WashingtonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →